Introduction
Welcome to the Scope Highlights guide for the Annals of Medical and Surgical Dermatology, a fast, practical read that shows what we accept and how to position your paper. Authors often ask about dermatology journal aims and scope and how that translates into publishable articles. Below, you’ll find the Annals of Medical and Surgical Dermatology journal scope broken into clear sections with topical examples, study designs we like, and concise submission tips.
At a glance, we welcome:
- Original research and rigorous reviews
- Methodologically sound case series and case reports
- Translational and implementation studies
- Bench-to-bedside and device-based innovations
- Trial protocols, meta-analyses, and practice guidelines
Ready to proceed? See our Author Guidelines for formatting, reporting standards, and ethical approvals, or jump to Submit Manuscript when your files are final.
Medical, Surgical & Cosmetic Dermatology
AMSD publishes clinically impactful work across Medical, Surgical & Cosmetic Dermatology, prioritizing evidence that can change practice.
- Clinical dermatology: real-world cohorts, diagnostic yield, pragmatic outcomes
- Dermatologic surgery: complication rates, skin biopsy technique, excision margins
- Mohs surgery: indications, reconstructive planning, recurrence
- Cosmetic dermatology: lasers, fillers, peel science, durability of effect
- Patient-reported outcomes: validated scales, satisfaction, quality-of-life shifts
Mini-CTA: Cross-check reporting against our Author Guidelines, then Submit Manuscript with high-quality figures and de-identified photos.
Dermatopathology
Dermatopathology submissions should connect microscopic patterns to bedside decisions.
- Skin biopsy pathology studies linking patterns to therapy selection
- Immunohistochemistry in dermatology: markers that refine challenging differentials
- Diagnostic accuracy analyses: sensitivity/specificity with confidence intervals
- Frozen section utility and concordance with permanent sections
- Clinicopathologic correlation: one figure, one message, one management implication
- Algorithmic diagnosis: reproducible flowcharts validated on external sets
Mini-CTA: Ensure scalebars and representative fields; see Author Guidelines and Submit Manuscript.
Immunodermatology
Immunodermatology welcomes mechanistic to clinical research that advances targeted care.
- Autoimmune blistering diseases: activity indices, relapse predictors
- Pemphigus and bullous pemphigoid: steroid-sparing strategies, safety profiles
- Cutaneous lupus: flare signatures, composite outcomes
- Th17 pathway: translational biomarkers, responder phenotypes
- JAK inhibitors: dosing, monitoring, infection risk stratification
Mini-CTA: Pre-register trials and include safety tables; see Author Guidelines before submitting.
Skin Disorders
We cover common to complex Skin Disorders with robust methodology and clear takeaways.
- Acne vulgaris: comparative effectiveness, antibiotic stewardship
- Atopic dermatitis/eczema: adherence, caregiver burden, long-term control
- Psoriasis: treat-to-target pathways, comorbidity screening
- Alopecia areata: durability after withdrawal, relapse kinetics
- Urticaria: step-up algorithms, antihistamine responsiveness
- Hidradenitis suppurativa: staging transitions, surgery-drug combinations
- Rare genodermatoses: genotype-phenotype with management implications
Mini-CTA: Use CONSORT/STROBE/PRISMA as applicable; then Submit Manuscript.
Microdermabrasion
AMSD publishes data-driven appraisals of Microdermabrasion in modern practice.
- Dermabrasion vs microdermabrasion: indication clarity and outcome contrasts
- Hyperpigmentation: risk factors by Fitzpatrick type; prevention strategies
- Acne scars: validated scar scales and blinded raters
- Randomized controlled trials and split-face studies with effect sizes
- Adverse events: rates, resolution timelines, mitigation steps
Mini-CTA: Include device parameters and operator training detail; see Author Guidelines.
Microneedling with radiofrequency
We welcome controlled evaluations of Microneedling with radiofrequency (include “RF microneedling” once in text).
- Acne scarring: long-term durability and histologic change
- Skin laxity: objective firmness metrics and patient satisfaction
- Striae: combined protocols and maintenance schedules
- Combination therapy: peel/energy synergies with safety tracking
- Histologic remodeling: collagen/elastin endpoints, biopsy timing
Mini-CTA: Report energy, pass count, needle depth, analgesia; then Submit Manuscript.
Skin Cancer
Skin Cancer papers should sharpen detection, treatment, and follow-up.
- Basal cell carcinoma and squamous cell carcinoma: margin science, clearance rates
- Melanoma: stage migration, adjuvant therapy uptake, survival modelling
- Actinic keratosis: field therapy adherence and cost-effectiveness
- Non-melanoma skin cancer: risk tools for high-risk sites
- Surgical margins and Mohs outcomes: function-preserving reconstruction
- Dermoscopy: pattern libraries linked to histology
- AI diagnostics: prospective validation and bias audits
Mini-CTA: Add decision curves and net benefit; consult Author Guidelines before submitting.
Teledermatology & digital health
We seek pragmatic evidence for Teledermatology & digital health that improves reach and quality.
- Teledermatology models: triage accuracy, time-to-treatment
- Store-and-forward dermatology: image quality standards, throughput
- Digital dermatology: app validation, adherence features
- AI in dermatology: human-in-the-loop safety and equity metrics
- Implementation science: cost, workflow, clinician uptake
- Equity of access: rurality, connectivity, language inclusion
Mini-CTA: Provide de-identified image sets and protocols; see Author Guidelines.
Vitiligo & pigmentary disorders
We welcome precise, patient-centred work on Vitiligo & pigmentary disorders.
- Vitiligo: repigmentation kinetics, maintenance therapy
- Melasma: endocrine links, recurrence prevention
- Post-inflammatory hyperpigmentation: risk stratification and counselling
- Phototherapy: dose schedules, eye/skin safety monitoring
- Topical/systemic therapy: stepwise algorithms and safety labs
- Objective colorimetry: device calibration, inter-rater reliability
Mini-CTA: Use standardised photography and colour metrics; then Submit Manuscript.
Regenerative & Biotech Dermatology
AMSD features Regenerative & Biotech Dermatology with rigorous endpoints.
- Regenerative dermatology and biotech dermatology pipelines with translational plans
- Platelet-rich plasma: dosing, spins, indications beyond hair
- Exosomes: characterization, GMP readiness, clinical signal
- Stem-cell approaches: safety, immune risk, functional outcomes
- Tissue engineering: graft integration, vascularisation metrics
- Wound healing: time-to-closure, pain, scar quality
Mini-CTA: Include manufacturing and quality controls; consult Author Guidelines.
Cancer Biomarkers
We publish clinically meaningful Cancer Biomarkers for earlier detection and precise care.
- Skin cancer biomarkers with utility beyond staging
- Melanoma biomarkers: prognostic and predictive panels
- ctDNA dynamics and clearance thresholds
- Liquid biopsy feasibility in routine clinics
- Companion diagnostics tied to therapy choice
- Analytical validity and clinical validity frameworks
Mini-CTA: Provide assay reproducibility and cost considerations; then Submit Manuscript.
Pediatric dermatology
Pediatric dermatology (also “paediatric dermatology”) spans newborn to adolescent care.
- Infant eczema: caregiver education and flare prevention
- Hemangioma: early risk tools and treatment timing
- Pediatric psoriasis: growth, vaccination, mental health screening
- Genetic skin disorders: multidisciplinary care pathways
- Quality of life: age-appropriate, validated measures
Mini-CTA: Add assent/consent details and safety monitoring; see Author Guidelines.
Therapeutics & Clinical Trials in Dermatology
We prioritize robust Therapeutics & Clinical Trials in Dermatology with transparent methods.
- Dermatology clinical trials: randomization, blinding, protocol access
- Dermatology therapeutics: dosing logic, monitoring schedules
- Biologics and JAK inhibitors: long-term safety and immunization plans
- Endpoints: EASI, PASI, IGA with MCID reporting
- CONSORT diagrams, registries, and data-sharing statements
- Safety: AE adjudication, risk mitigation, stopping rules
Mini-CTA: Align outcomes with payer and patient priorities; then Submit Manuscript.
How to decide if your manuscript fits
Before you write the cover letter, quickly assess fit.
- Does the research answer a clinically relevant dermatology question?
- Are methods and outcomes standardized and validated?
- Is the message clear enough for one figure/one table to carry it?
- Would a busy clinician change something tomorrow after reading it?
- Are ethics, data availability, and images fully compliant?
If unsure, send a brief pre-submission enquiry summarizing aim, design, sample size, primary outcome, and key findings. We’ll advise fit fast.
FAQ
Q: Do you accept Teledermatology & digital health audits and implementation studies?
A: Yes especially those with patient-centered outcomes, cost per resolved referral, and equity metrics.
Q: What counts as publishable Dermatopathology beyond classic case reports?
A: Diagnostic accuracy, clinicopathologic correlation that changes management, validated IHC panels, and reproducible algorithms.
Q: Is Cosmetic Dermatology welcome, and what evidence is best?
A: Yes comparative studies, split-face trials, histology-backed mechanisms, durability beyond 3–6 months, and comprehensive adverse-event reporting.
Q: What strengthens dermatology clinical trials submissions?
A: Prospective registration, CONSORT adherence, clinically meaningful endpoints (PASI/EASI/IGA with MCIDs), robust safety oversight, and transparent statistics.
Q: Do you consider negative or neutral results?
A: Absolutely if adequately powered, methodologically sound, and clinically informative.
Q: Can early career teams submit?
A: Yes. Include senior oversight where needed and adhere strictly to reporting guidelines.
Conclusion & CTA
Annals of Medical and Surgical Dermatology’s scope is broad by design, yet curated for clinical impact use this guide to match your study with our sections and to craft a clear, data-forward narrative. For authors comparing venues by dermatology journal aims and scope, Annals of Medical and Surgical Dermatology offers rapid, fair assessment and practical readership across clinical, surgical, cosmetic, and translational fronts.
Next steps:
- Review the Aims & Scope pillar page for detailed fit cues
- Format per Author Guidelines (checklists inside)
- Start your Submit Manuscript workflow or Propose Special Issue if leading a theme
About Annals of Medical and Surgical Dermatology (Quick Facts)
- Title: Annals of Medical and Surgical Dermatology (ISSN: 3048-5185)
- Discipline: Medical sciences (dermatology)
- Frequency: Quarterly | Language: English | Format: Online
- Launch Year: 2023
- Editorial Values: Double-blind peer review; translational relevance; ethical rigor
- Scope highlights: Skin diseases, skin cancer, dermatologic surgery, dermatopathology, pediatric/geriatric dermatology, immunodermatology, hair and nail disorders
- Register & submit: https://www.reseaprojournals.com/journals/emsystem/register_user
Soft Call for Papers:
AMSD is inviting high-quality submissions across the sections above. If you have a focused dataset with clear clinical implications or a protocol, meta-analysis, or implementation study ready review our Author Guidelines and Submit Manuscript today.
For more Interesting Blog please visit our Blog site.